{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:21:18Z","timestamp":1789402878674,"version":"build-2803163510"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Carbapenem-resistant Enterobacterales (CRE) pose a significant global public health threat. Resistance among CRE is particularly complex, owing to numerous possible resistance mechanisms and broad definitions. We aimed to characterize the clinical and molecular profiles of CRE in the South Texas region.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We compared the clinical, genotypic, and phenotypic profiles of carbapenemase producing Enterobacterales (CPE) with those of non-carbapenemase producers (NCPE) isolated from South Texas, United States between 2011 and 2019. Molecular characteristics and resistance mechanisms were analyzed using whole-genome sequences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The majority (59%) of the CRE isolates were NCPE while 41% of isolates harbored carbapenemases, predmonantly <jats:italic>bla<\/jats:italic><jats:sub>KPC<\/jats:sub>-type. The most common CPE was <jats:italic>Klebsiella pneumoniae<\/jats:italic> while majority of <jats:italic>Enterobacter cloacae<\/jats:italic> and <jats:italic>Escherichia coli<\/jats:italic> were NCPE Among <jats:italic>K. pneumoniae<\/jats:italic>, the clonal group 307 has emerged as a predmoninant group and was associated with as many CRE infections as the previous common clonal group 258. Patients with NCPE compared to CPE infections were associated with higher antimicrobial exposure prior to culture collection (days of therapy, 795 vs. 242; <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and emergency department visits within past 90 days (22% vs. 4%; <jats:italic>p<\/jats:italic> = 0.011). The all cause 30-day mortality was 21%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study highlights the diversity of resistance mechanisms underlying CRE in South Texas, with 59% not harboring a carbapenemase. Individuals with NCPE infections were more likely to have had prior antimicrobial therapy and emergency department visits compared to those with CPE. Identification and distinction of these mechanisms by rapid identification of species and carbapenemase would allow for optimal treatment and infection control efforts.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2020.623574","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T15:16:34Z","timestamp":1612970194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Predominance of Non-carbapenemase Producing Carbapenem-Resistant Enterobacterales in South Texas"],"prefix":"10.3389","volume":"11","author":[{"given":"Cody A.","family":"Black","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonhee","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S.","family":"Dallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Gawrys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Benavides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Jui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Shurko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1089\/mdr.2018.0306","article-title":"Emergence of IncFIA plasmid-carrying blaNDM-1 among Klebsiella pneumoniae and Enterobactercloacae isolates in a tertiary referral hospital in Mexico.","volume":"25","author":"Alc\u00e1ntar-Curiel","year":"2019","journal-title":"Microb. Drug Resist."},{"key":"B2","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1086\/605922","article-title":"Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia.","volume":"30","author":"Borer","year":"2009","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B3","doi-asserted-by":"publisher","year":"2019","journal-title":"Antibiotic Resistance Threats in the United States, 2019.","DOI":"10.15620\/cdc:82532"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3201\/eid2109.150198","article-title":"Improved phenotype-based definition for identifying carbapenemase producers among carbapenem-resistant Enterobacteriaceae.","volume":"21","author":"Chea","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"B5","year":"2018","journal-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Twenty-Eighth Edition: M100"},{"key":"B6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.","volume":"20","author":"Duin","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0969-2126(99)80055-0","article-title":"Crystal structure and functional characterization of OmpK36, the osmoporin of Klebsiella pneumoniae.","volume":"7","author":"Dutzler","year":"1999","journal-title":"Structure"},{"key":"B8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1469-0691.2011.03515.x","article-title":"Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy.","volume":"18","author":"Findlay","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7196\/SAMJ.2018.v109i1.13696","article-title":"Genomic characterisation of Klebsiella michiganensis co-producing OXA-181 and NDM-1 carbapenemases isolated from a cancer patient in uMgungundlovu District, KwaZulu-Natal Province, South Africa.","volume":"109","author":"Founou","year":"2018","journal-title":"S. Afr. Med. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1001\/jama.2015.12480","article-title":"Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013.","volume":"314","author":"Guh","year":"2015","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ijantimicag.2018.03.020","article-title":"Role of association of OmpK35 and OmpK36 alteration and blaESBL and\/or blaAmpC genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae.","volume":"52","author":"Hamzaoui","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1128\/JCM.42.6.2701-2706.2004","article-title":"Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey.","volume":"42","author":"Hasdemir","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections.","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nrmicro1994","article-title":"The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria.","volume":"6","author":"Pag\u00e8s","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1099\/jmm.0.038083-0","article-title":"Acquisition of carbapenem resistance in multiresistant Klebsiella pneumoniae strains harbouring blaCTX-M-15, qnrS1 and aac(6\u2032)-Ib-cr genes.","volume":"61","author":"Ruiz","year":"2012","journal-title":"J. Med. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae.","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B17","year":"2020","journal-title":"Global Priority List Of Antibiotic-Resistant Bacteria To Guide Research, Discovery, And Development Of New Antibiotics WHO."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-11756-y","article-title":"OmpK36-mediated carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo.","volume":"10","author":"Wong","year":"2019","journal-title":"Nat. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial.","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect. Dis. Ther"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2020.623574\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T15:16:37Z","timestamp":1612970197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2020.623574\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":19,"alternative-id":["10.3389\/fmicb.2020.623574"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2020.623574","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"article-number":"623574"}}